Levormeloxifene

Levormeloxifene (pronounced: le-vor-me-lox-i-fene) is a Selective Estrogen Receptor Modulator (SERM) that was under development for the treatment of osteoporosis and breast cancer, but was discontinued due to safety concerns.

Etymology

The term "Levormeloxifene" is derived from the Latin word "levo" meaning left, "mel" meaning honey, and "oxi" referring to oxygen. "Fene" is a common suffix used in the naming of drugs that act as estrogen receptor modulators.

Pharmacology

Levormeloxifene acts as an antagonist at estrogen receptors, specifically ERα and ERβ. This means it blocks the effects of estrogen in some tissues, such as the breasts and uterus, while acting as an estrogen in other tissues, such as the bones.

Clinical Trials

Clinical trials of Levormeloxifene were conducted for the treatment of osteoporosis and breast cancer. However, the drug was discontinued due to an increased risk of venous thromboembolism and endometrial cancer.

Related Terms

External links

Medical encyclopedia article on Levormeloxifene
Wikipedia's article - Levormeloxifene

This WikiMD article is a stub. You can help make it a full article.

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

Levormeloxifene